Evidence map›Paper›PMID 37370384›Full record

ArticleAntibiotics (Basel, Switzerland)2023

Design, Synthesis, and Structure-Activity Relationship Studies of New Quinone Derivatives as Antibacterial Agents.

Juan Andrades-Lagos, Javier Campanini-Salinas, América Pedreros-Riquelme, Jaime Mella, Duane Choquesillo-Lazarte, P P Zamora, Hernán Pessoa-Mahana, Ian Burbulis, David Vásquez-Velásquez

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Juan Andrades-LagosFacultad de Medicina y Ciencia, Universidad San Sebastián, Santiago 7510157, Chile.ORCID 0009-0008-1666-0018
Javier Campanini-SalinasDrug Development Laboratory, Faculty of Chemical and Pharmaceutical, Sciences, Universidad de Chile, Santiago 8380492, Chile.ORCID 0000-0002-7358-409X
América Pedreros-RiquelmeDrug Development Laboratory, Faculty of Chemical and Pharmaceutical, Sciences, Universidad de Chile, Santiago 8380492, Chile.
Jaime MellaInstituto de Química y Bioquímica, Facultad de Ciencias, Universidad de Valparaíso, Playa Ancha, Valparaíso 2360102, Chile.ORCID 0000-0002-2434-8461
Duane Choquesillo-LazarteLaboratorio de Estudios Cristalográficos, IACT (CSIC-UGR), Av. de las Palmeras 4, 18100 Armilla, Spain.ORCID 0000-0002-7077-8972
P P ZamoraDepartamento de Química y Biología, Facultad de Ciencias Naturales, Universidad de Atacama, Copiapó 1530000, Chile.ORCID 0000-0001-6293-8756
Hernán Pessoa-MahanaDepartamento de Química Orgánica y Fisicoquímica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380492, Chile.
Ian BurbulisCentro de Investigación Biomédica, Facultad de Medicina y Ciencias, Universidad San Sebastián, Sede de la Patagonia, Puerto Montt 5501842, Chile.
David Vásquez-VelásquezDrug Development Laboratory, Faculty of Chemical and Pharmaceutical, Sciences, Universidad de Chile, Santiago 8380492, Chile.ORCID 0000-0003-0635-4857

Funding

CONICYT Beca Doctorado Nacional, J.A.L. 21130628CONICYT Beca Doctorado Nacional, J.C.S. 21130643FONDECYT 11110516FONDECYT 1191737FONDECYT 79100006
6 · The paper itself

Abstract

Resistance to antibacterial agents is a growing global public health problem that reduces the efficacy of available antibacterial agents, leading to increased patient mortality and morbidity. Unfortunately, only 16 antibacterial drugs have been approved by the FDA in the last 10 years, so it is necessary to develop new agents with novel chemical structures and/or mechanisms of action. In response to this, our group takes up the challenge of designing a new family of pyrimidoisoquinolinquinones displaying antimicrobial activities against multidrug-resistant Gram-positive bacteria. Accordingly, the objective of this study was to establish the necessary structural requirements to obtain compounds with high antibacterial activity, along with the parameters controlling antibacterial activity. To achieve this goal, we designed a family of compounds using different strategies for drug design. Forty structural candidates were synthesized and characterized, and antibacterial assays were carried out against high-priority bacterial pathogens. A variety of structural properties were modified, such as hydrophobicity and chain length of functional groups attached to specific carbon positions of the quinone core. All the synthesized compounds inhibited Gram-positive pathogens in concentrations ranging from 0.5 to 64 µg/mL. Two derivatives exhibited minimum inhibitory concentrations of 64 µg/mL against

Indexed as

antibacterial activityantibacterial agentsCraig plotdrug discoveryEnterococcus faeciumFree-WilsonKlebsiella pneumoniaemethicillin-resistant Staphylococcus aureusquinone-antibioticsquinonic-antibioticsstructure–activity relationshipssynthesis

Identifiers

PMID37370384
PMCPMC10295782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.